Ironshore Pharmaceuticals to Present Data at the 6th
World Congress on ADHD

April 19, 2017 09:56 AM Eastern Time

GEORGE TOWN, Cayman Islands--(EON: Enhanced Online News)--Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly
owned subsidiary of Highland Therapeutics Inc., today announced that it
will be presenting clinical data for its investigational drug candidate
HLD200 (delayed-release and extended-release methylphenidate), as well
as rating-scale validation work at the 6th World Congress on
ADHD (Attention Deficit / Hyperactivity Disorder), being held in
Vancouver, British Columbia from April 20-23, 2017.

“We are delighted to be sharing pivotal trial data and validation work
we have conducted in support of two important functional rating scales:
the Before School Functioning Questionnaire, or BSFQ, and the Parent
Rating of Evening and Morning Behavior – Revised, or PREMB-R, at the
World Congress on ADHD”

“We are delighted to be sharing pivotal trial data and validation work
we have conducted in support of two important functional rating scales:
the Before School Functioning Questionnaire, or BSFQ, and the Parent
Rating of Evening and Morning Behavior – Revised, or PREMB-R, at the
World Congress on ADHD,” said Dr. Randy Sallee, Chief Medical Officer.
“Our caregiver survey data, which will also be shared at the conference,
support the fact that significant unmet medical needs exist in the
treatment of ADHD. Ironshore invites all healthcare professionals
attending the World Congress on ADHD to visit with us to learn more
about the exciting work we are doing.”

Efficacy and safety of HLD200, a novel delayed-release and
extended-release methylphenidate formulation, in children with
Attention-Deficit/Hyperactivity Disorder: Results from a pivotal phase 3
trial

Poster #: 011

Dose proportionality and effect of food on the pharmacokinetics of
HLD200, a novel delayed-release and extended-release methylphenidate
formulation in healthy adults

Guided Poster Tour Session P-19: Quality of life / Caregiver burden I

Friday, April 21, 2017, 2:30pm to 4pm PDT

Poster #: 006

Impact on the family unit of early morning functional impairments in
stimulant-treated children and adolescents with
Attention-Deficit/Hyperactivity Disorder

Guided Poster Tour Session P-05: Diagnosis I

Friday, April 21, 2017, 2:30pm to 4pm PDT

Poster #: 007

Parent ratings on the before school functioning questionnaire (BSFQ) in
youths with and without a history of ADHD: Results from a normative
survey

Poster #: 006

Normative survey data for the parent rating of evening and morning
behaviour scale, revised (PREMB-R) in youths with and without a history
of ADHD

Specific information about the data contained in the posters is
embargoed until the start of the meeting.

About Ironshore Pharmaceuticals & Development, Inc.

Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary
of Highland Therapeutics Inc., is a pharmaceutical company that is
leveraging its proprietary technology, DELEXIS®, to optimize the
delivery of previously approved drug products.

This press release contains forward-looking information, which reflects
Ironshore’s current expectations regarding future events.
Forward-looking information is based on a number of assumptions and is
subject to a number of risks and uncertainties, many of which are beyond
Ironshore’s control that could cause actual results and events to differ
materially from those that are disclosed in or implied by such
forward-looking information. These forward-looking statements are made
as of the date of this press release and, except as expressly required
by applicable law, Ironshore assumes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.